Manganese suppresses tumor growth through hyper-activating IRE1α

Area of Science:

• Cellular Biology
• Cancer Research
• Biochemistry

Background:

• The unfolded protein response (UPR) pathway, particularly involving IRE1α (inositol-requiring enzyme 1 alpha) and XBP1 (X-box binding protein 1), is crucial for cellular adaptation to endoplasmic reticulum stress.
• Tumor cells exploit this pathway to survive harsh tumor microenvironments, driving cancer progression.
• Current IRE1α inhibitors show promise in preclinical cancer trials but lack clinical application.

Purpose of the Study:

• To investigate the potential of activating IRE1α as a tumor suppression strategy, contrasting with the typical inhibition approach.
• To identify novel activators of the IRE1α pathway for cancer therapy.

Main Methods:

• Identification of manganese ions (Mn2+) as a direct activator of IRE1α.
• Characterization of Mn2+ interaction with the cytosolic domain of IRE1α.
• Assessment of Mn2+ effects on downstream pro-apoptotic and pro-survival signaling pathways.
• Evaluation of Mn2+ efficacy in limiting tumor growth in a xenograft mouse model, assessing IRE1α dependency.

Main Results:

• Divalent manganese ion (Mn2+) was identified as a potent activator of IRE1α.
• Mn2+ directly binds to the cytosolic portion of IRE1α, enhancing its pro-apoptotic signaling.
• The pro-survival signaling arm of the UPR was not augmented by Mn2+.
• Tumor growth was significantly limited in a xenograft model in an IRE1α-dependent manner.

Conclusions:

• Pharmacological activation of IRE1α, using agents like Mn2+, represents a promising and potentially underestimated therapeutic avenue for cancer treatment.
• Targeting IRE1α through activation, rather than inhibition, offers a novel strategy to induce cancer cell death and suppress tumor progression.